MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED

Mallinckrodt Pharmaceuticals Ireland Limited is a key player in the Irish pharmaceutical landscape, operating under the umbrella of two distinct businesses that emerged from a 2025 merger with Endo. The first, Keenova Therapeutics, concentrates on specialty medicines for patients with rare, stigmatised or otherwise unmet medical needs, covering therapeutic areas such as immunology, urology, hepatology, ophthalmology, orthopaedics and critical care. The second, Par Health, supplies the essential foundations of modern healthcare, developing high-quality generic medicines, sterile injectables and active pharmaceutical ingredients (APIs) supported by a robust, U.S.-advantaged manufacturing network and a global workforce of more than 4,000 professionals.

Together, these entities combine cutting-edge specialty therapeutics with reliable, cost-effective essential medicines, delivering a comprehensive portfolio that serves patients, clinicians and healthcare providers across Ireland and beyond. Their dual focus ensures that both innovative treatments and the everyday medicines that keep health systems running are produced to the highest standards.